Baring To Acquire Lumenis

Top Aesthetic Laser Provider Sold

Baring Private Equity Asia (BPEA) has agreed to acquire Lumenis, a provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.

Lumenis has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA.

AbbVie to Acquire Allergan

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction with an equity value of approximately $63 billion. Once the acquisiton is completed, AbbVie will continue maintain its principal executive offices in North Chicago under the leadership of current chairman and CEO Richard A. Gonzalez. Two members of Allergan’s board of directors, including chairman and CEO Brent Saunders, will join AbbVie’s board.

Apax Partners to Acquire Syneron

Syneron Candela

Aesthetic device manufacturer Syneron Medical has entered into an agreement with Apax Partners, a global private equity advisory firm, under which an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron-Candela for $11.00 per share in cash in a transaction valued at approximately $397 million.

Viscot Medical Acquires OP Marks

Medical products provider Viscot Medical has acquired OP Marks, founded in 2004 to manufacture patient safety products. Effective October 3, 2014, this acquisition makes Viscot the leading manufacturer of surgical skin markers, medication labels and patient safety products. The company will be run as a division of Viscot, called OP Marks Medical.

“The joining of our two firms will strengthen our position in the surgical marketplace and consolidate our efforts to reduce patient safety errors and improve surgical outcomes,” said Gary Pieringer, CEO of Viscot Medical.

Merz To Acquire Ulthera


Merz and Ulthera have entered into a definitive merger agreement, pursuant to which Merz will acquire global medical device company Ulthera, which developed the ultrasound-based Ultherapy technology for noninvasive skin tightening and lifting. Valued at up to $600 million in upfront cash and milestone payments, the acquisition is the largest in Merz’s history.

Valeant Completes Acquisiton of PreCision and Submits HSR Filing for Proposed Acquisition Of Allergan

Valeant Pharmaceuticals International has completed its acquisition of PreCision Dermatology, which develops and markets high-quality dermatology products, including Locoid, Hylatopic, and Clindagel.

On July 14, 2014, Valeant announced it had filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan.

Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant

Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant

Allergan’s Board of Directors, after consulting with its independent financial and legal advisors, has unanimously determined that the latest unsolicited proposal from Valeant Pharmaceuticals to acquire Allergan substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the Company and its stockholders.

Valeant Moves To Acquire Allergan

Valeant Proposes Merger with Allergan

On April 22, Valeant Pharmaceuticals International, in conjunction with Pershing Square Capital Management, submitted a merger proposal to the Board of Directors of Allergan. Under the terms of the proposed merger, each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant common stock.

If the merger is completed, Allergan shareholders will own 43% of the combined company and continue to participate in the expected value creation of the combined company.

Syneron Medical Acquires New Star Lasers

Syneron Medical has entered into an agreement to acquire New Star Lasers, which conducts business as CoolTouch, for approximately $11 million in cash and earn out based on certain milestones of up to $4 million until end of 2015. New Star Lasers develops, manufactures and markets the CoolTouch family of aesthetic devices. Syneron anticipates the acquisition will close this month (March 2014).